Skip to main content

Advertisement

SpringerLink
Log in

DIABETES

A new class of drug in the diabetes toolbox

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

The DAWN and SEED trials demonstrate the potential of glucokinase activators for the treatment of type 2 diabetes, but how they fit in the overall treatment algorithm remains to be determined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Positioning dorzagliatin in future treatment paradigms.

References

  1. Matschinsky, F. M. Trends Pharmacol. Sci. 34, 90–99 (2013).

    Article  CAS  Google Scholar 

  2. Grimsby, J. et al. Science 301, 370–373 (2003).

    Article  CAS  Google Scholar 

  3. Guertin, K. R. & Grimsby, J. Curr. Med. Chem. 13, 1839–1843 (2006).

    Article  CAS  Google Scholar 

  4. The Dawn Study Group. Nat. Med. https://doi.org/10.1038/s41591-022-01803-5 (2022).

  5. The SEED Study Group. Nat. Med. https://doi.org/10.1038/s41591-022-01802-6 (2022).

  6. De Ceuninck, F. et al. Br. J. Pharmacol. 168, 339–353 (2013).

    Article  Google Scholar 

  7. Zhu, D. et al. Lancet Diabetes Endocrinol 6, 627–636 (2018).

    Article  CAS  Google Scholar 

  8. Vella, A. et al. Sci. Transl. Med. 11, eaau3441 (2019).

    Article  CAS  Google Scholar 

  9. Klein, K. R. et al. Diabetes Care 44, 960–968 (2021).

    Article  CAS  Google Scholar 

  10. Chen, L. et al. Diabetes 70, 117–LB (2021).

    Article  Google Scholar 

  11. Miao, J. et al. Clin. Transl. Sci. 15, 548–557 (2022).

    Article  CAS  Google Scholar 

  12. American Diabetes Association Professional Practice Committee. Diabetes Care 45, S125–S143 (2022).

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC, USA

    Klara R. Klein & John B. Buse

Authors
  1. Klara R. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John B. Buse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John B. Buse.

Ethics declarations

Competing interests

K.R.K. and J.B.B. have worked with vTv Therapeutics, the developers of the GKA TTP-399, as investigators and collaborators without direct financial benefit. J.B.B. has provided consultation to Novo Nordisk, with fees paid to the University of North Carolina; has grant support from Dexcom, NovaTarg, Novo Nordisk, Sanofi, Tolerion and vTv Therapeutics; is a consultant with personal compensation from Alkahest, Altimmune, Anji, AstraZeneca, Bayer, Boehringer-Ingelheim, CeQur, Cirius Therapeutics Inc., Dasman Diabetes Center (Kuwait), Eli Lilly, Fortress Biotech, GentiBio, Glycadia, Glyscend, Janssen, Mediflix, Medscape, Mellitus Health, Pendulum Therapeutics, Praetego, Stability Health, Valo and Zealand Pharma; and has received stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego and Stability Health.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klein, K.R., Buse, J.B. A new class of drug in the diabetes toolbox. Nat Med 28, 901–902 (2022). https://doi.org/10.1038/s41591-022-01783-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-01783-6

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation